CannaRiskCon 1.0, a panel discussion forum sponsored by Norris McLaughlin, The John Morgan McLachlan Agency, and New Ventures Consulting, will include in-depth Q&A-style conversations about the inherent legal liabilities and potential business risks facing the cannabis industry. This inaugural event will take place on January 29, 2020, at the Bridgewater Manor in Bridgewater, New Jersey.
Featuring leading experts risk management, insurance coverage, and the ever-expanding discipline of cannabis law, growers and dispensary operators from all levels of management and ownership will receive actionable information takeaways to help protect themselves from risk and liability and ensure their companies are successful.
Registration for this event is FREE, but is limited to the first 100 people who register! The information and takeaways from this event will be most valuable to growers and dispensary owners already invested in the industry, as well as those interested in starting a cannabis business or introducing cannabis products to their existing business. Ancillary service providers, vendors, distributors, and supply chain manufacturers are also encouraged to attend. Whatever role your business plays in delivering cannabis products to this fast-growing market, this is one program you will not want to miss.
When: January 29, 2020
8:00 a.m. – 2:30 p.m.
Where: Bridgewater Manor
Bridgewater Township, NJ 08807
About the Norris McLaughlin Panelist
Eric Alvarez concentrates his practice on high-stakes, complex commercial litigation in both state and federal court. He represents businesses of all shapes and sizes—from closely-held partnerships to international corporations—as well as individuals, in a wide range of litigation matters, including general commercial litigation, consumer fraud, products liability, and mass tort litigation. Eric handles and coordinates multi-jurisdictional cases through all stages of litigation, up to and including trial. He is also a member of the firm’s Cannabis Law Practice Group. He advises clients on compliance with state and federal laws and regulations relating to the production, research, and testing of cannabis and cannabis-derived products such as cannabidiol (“CBD”).